BHA Acne Serum & Exfoliating Toner: Salicylic Acid 0.5–2% Formulation Guide

Overview #

If your brand is targeting acne-prone skin, salicylic acid is still the most defensible active you can put in a serum or toner. Not because it’s trendy — it’s not — but because the mechanism is genuinely suited to the problem. It’s oil-soluble, it gets into the follicle, and at the right pH it actually exfoliates inside the pore rather than just on the surface. The question we get from almost every brand partner isn’t “should we use salicylic acid” — it’s “what concentration, what pH, and what format will actually work without destroying our regulatory pathway.” That’s what this guide answers.

Salicylic Acid Grades, Concentrations, and What They Actually Do #

Not all salicylic acid inputs are the same, and this is where a lot of briefs go wrong before we even open a beaker.

Pharmaceutical-grade salicylic acid (99%+ purity) is what we use for any product making an acne claim in a regulated market. Cosmetic-grade material typically runs 97–98% purity, which is fine for exfoliating toners positioned as “pore-refining” without drug claims. The difference matters less in the formula and more in your regulatory filing. If you’re selling into the US and want to use OTC monograph language — “helps prevent acne,” “treats acne” — you need to be on the right side of that purity spec and your concentration needs to sit between 0.5% and 2.0% per the FDA Cosmetics Guidelines and the associated OTC Drug Monograph framework.

In our lab, we work across the full 0.5–2.0% range regularly. Here’s what we actually observe at each level:

At 0.5%, you get meaningful exfoliation with very low irritation risk. This is the right call for sensitive-acne skin, first-time users, or any brand that wants to layer salicylic acid with other actives like niacinamide or azelaic acid without stacking irritation. At 1.0–1.5%, you’re in the sweet spot for most acne serums — visible pore-clearing effect within 4–6 weeks, tolerable for most Fitzpatrick types. At 2.0%, efficacy is real but so is the dryness and potential barrier disruption. We almost always push back when a brand asks for 2% in a daily-use serum. A leave-on 2% product used twice daily is a fast track to a compromised barrier and a customer complaint.

pH is the variable most brands underestimate. Salicylic acid’s pKa is 2.97. For meaningful free-acid activity, you need to be below pH 4.0. We formulate most of our acne serums at pH 3.2–3.8. Drop below 3.0 and you’re in a different conversation — consumer tolerance drops sharply, and in the EU you start brushing against the EU Cosmetics Regulation 1223/2009 framework around product safety assessments for low-pH leave-on products. Most brands don’t realize this until we tell them.

The format — serum versus toner — changes the formulation more than the concentration does. Toners are typically water-thin, applied with a cotton pad or patted in, and rinsed or left on depending on the brief. Serums are leave-on, often with a more complex vehicle. In a toner, we can get away with a simpler preservative system and a more aggressive pH because contact time is shorter. In a serum, we have to think harder about long-term skin compatibility and packaging interaction.

The Comparison: Formats, Concentrations, and Regulatory Fit #

This is the table we mentally run through every time a new brief lands on our desk. It’s not exhaustive, but it covers the decisions that actually matter.

A few things this table doesn’t capture: the EU requires a Cosmetic Product Safety Report (CPSR) for any leave-on product at low pH regardless of SA concentration — that’s a cost and timeline item your regulatory team needs to budget. The NMPA Cosmetic Regulation in China classifies salicylic acid as a restricted ingredient, capped at 2% in rinse-off and 0.5% in leave-on products for non-drug cosmetics. If you’re building a China-facing SKU, the 2% leave-on serum is simply not an option without a drug registration pathway.

Encapsulated salicylic acid deserves its own note. We’ve been running more of these projects over the past two years, mostly driven by brands that want BHA efficacy without the low-pH constraint. The encapsulation releases SA at the skin surface, which means the bulk formula can sit at a skin-friendly pH 5.5–6.0. It works. But encapsulation adds roughly 2.5–3× the raw material cost compared to free SA, and the release kinetics vary by encapsulation technology. We’re still not fully convinced the clinical evidence for encapsulated SA matches free-acid SA at equivalent nominal concentrations. Our stability data is solid; the efficacy comparison is less clear.

Where Most Brands Get This Wrong #

The brief usually says: “We want 2% salicylic acid, low pH, leave-on serum, suitable for sensitive skin, and we want to launch in the US, EU, and China simultaneously.”

That brief has four problems in one sentence.

First, 2% leave-on at low pH is not suitable for sensitive skin. Full stop. Second, the US OTC pathway for a 2% acne product adds 3–6 months to your timeline and requires specific labeling, testing, and manufacturing compliance that most indie brands aren’t set up for. Third, the EU CPSR for a low-pH leave-on product is not a rubber stamp — a qualified safety assessor needs to sign off, and at pH below 3.5 that conversation gets harder. Fourth, China won’t register a 2% leave-on SA product as a cosmetic. You’d need a separate SKU or a different concentration for that market.

We almost always push back on this brief. Not to be difficult — because launching a product that fails regulatory review in one of your three target markets six months in is a much worse outcome than adjusting the brief now.

The other failure mode we see regularly: brands that want to combine salicylic acid with retinol in the same formula. Short answer — don’t. The pH required for free-acid SA activity (below 4.0) is incompatible with retinol stability (optimal at pH 5.0–6.0). You end up compromising both actives. We’ve had this conversation more times than we can count. The right answer is separate SKUs or a time-separated routine.

One pilot batch failure worth sharing: a brand came to us with a 1.5% SA toner formula they’d developed in-house at lab scale. Looked fine at 100g. We scaled to 150kg for the pilot run and by week 6 of preservative challenge testing, gram-negative contamination appeared. The issue traced back to the interaction between their chosen preservative system (phenoxyethanol/ethylhexylglycerin) and the low-pH environment — the preservative was technically in spec, but the combination of pH 3.4, high water activity, and a botanical extract they’d added created a microenvironment the preservative couldn’t hold at scale. We reformulated with a broader-spectrum system and added a chelating agent. Passed on the second run. This is usually where projects go sideways.

Clinical Evidence: What the Data Actually Shows #

The head-to-head data for salicylic acid in acne is actually pretty solid, especially compared to some of the newer actives we get briefed on. One well-designed double-blind RCT (n=60, 12 weeks, twice-daily application of 2% SA leave-on gel vs. vehicle control) showed a 49% reduction in non-inflammatory lesion count and a 36% reduction in inflammatory lesions versus baseline. The vehicle control group showed 11% and 8% reductions respectively. That’s a meaningful delta, and it’s consistent with what we see in consumer perception studies run by our brand partners.

What the clinical data doesn’t tell you — and what we’ve learned from our own batches — is the stability and tolerance story at scale. Most published studies use pharmaceutical-grade formulations with tight pH control. Real-world cosmetic products drift. We’ve seen pH creep of 0.2–0.3 units over 12 months in poorly buffered systems, which meaningfully changes the free-acid fraction and therefore the efficacy. Buffering your SA formula properly isn’t optional. We use citrate-phosphate or sodium citrate buffer systems to hold pH within ±0.15 units across a 12-month accelerated stability window at 40°C/75% RH per ICH Stability Guidelines.

The SCCS Scientific Opinion on salicylic acid (2019 opinion, updated considerations) is worth reading if you’re building EU-facing products. The SCCS concluded that SA at up to 2% in face products is safe for the general population but flagged specific concerns around use in children under 3 and around leave-on products at low pH for compromised skin. That opinion shapes how EU safety assessors approach CPSRs for these products.

For brands interested in how salicylic acid fits into a broader acne & blemish control routine architecture, the interaction with niacinamide and azelaic acid is worth understanding before you finalize your SKU lineup.

Preservative Systems, Packaging, and the Stability Variables Nobody Talks About #

Low-pH BHA formulas are actually easier to preserve than neutral-pH products in one sense — the acidic environment itself is hostile to many microorganisms. But that doesn’t mean you can under-preserve. We’ve seen brands try to use minimal preservative loads at pH 3.5 and call it “self-preserving.” It’s not a reliable strategy at commercial scale.

Our standard approach for a 1.0–1.5% SA serum at pH 3.2–3.8: phenoxyethanol at 0.8–1.0% combined with a chelating agent (EDTA disodium at 0.05–0.1% or sodium phytate for clean-label briefs). We run ISO 11930 challenge testing on every new formula — not just the finished product, but after 3 months of accelerated aging, because preservative efficacy can degrade as the formula ages. This is a step some smaller manufacturers skip. We don’t.

Packaging matters more than most brands expect for low-pH actives. Salicylic acid at pH below 4.0 will interact with certain metal components — avoid aluminum-lined tubes without a protective lacquer coating. We’ve had one project where the SA formula was discoloring by week 10 in an unlined aluminum tube. Switched to a lacquer-lined tube and the issue resolved. Airless pump packaging is our preferred recommendation for SA serums — it limits oxidation exposure and prevents pH drift from CO₂ absorption. Airless pump adds roughly $0.50–$0.90 per unit at MOQ 3,000 units. Most indie brands can absorb that. At MOQ 1,000, it starts to hurt the unit economics.

For brands exploring how encapsulation technology can change the packaging and pH constraints on BHA formulas, our encapsulation technology documentation covers the delivery system options in more detail.

Formulation Notes for Brand Partners #

When a new brief comes in for a BHA product, the first questions we ask are: What market are you launching in first? What’s the on-pack claim you’re building toward? And what’s your customer’s skin type — because “acne-prone” covers a huge range from oily teenage skin to dry adult hormonal acne, and those need different formulas.

If you’re US-first with an OTC acne claim, we’ll steer you toward 1.0–2.0% SA at pH 3.2–3.8 in a lightweight serum or toner vehicle, with full OTC compliance documentation. Timeline from brief to finished product is typically 16–20 weeks including stability and challenge testing.

If you’re EU-first or building a clean beauty positioning, we’ll likely recommend 0.5–1.0% SA at pH 3.5–4.2, possibly with encapsulated SA if your margin supports it, and we’ll build the CPSR dossier in parallel with formulation. That adds 4–6 weeks to the timeline but it’s not optional.

If you’re targeting combination skin with a “pore-refining” angle rather than a direct acne claim, we have a lot of flexibility — lower concentration, higher pH, more complex vehicle with hydrating actives to offset the exfoliation. These formulas are easier to stabilize, easier to register, and honestly easier to sell to a broader audience.

MOQ for a custom SA serum or toner starts at 1,000 units for simple formulas. Complex encapsulated systems typically require 3,000 units minimum to make the raw material economics work.

Frequently Asked Questions #

Q: We want to call it “2% Salicylic Acid” on pack and sell it in the US — do we need an OTC drug registration?

Yes, if you’re making any acne treatment claim. The FDA OTC monograph for acne (21 CFR 333) covers SA at 0.5–2.0% with specific labeling requirements. If you’re positioning it purely as an exfoliant with no acne claim, you may be able to stay in cosmetic territory — but that’s a regulatory call that needs a qualified US regulatory consultant, not just our formulation team.

Q: Can we combine salicylic acid with niacinamide in the same serum?

Yes, and it’s actually a good combination for acne-prone skin. Niacinamide helps offset the potential barrier disruption from low-pH SA. We typically formulate niacinamide at 4–5% in these blends and keep the pH at 3.5–4.0. The old concern about niacinamide converting to niacin at low pH is real but manageable — at pH above 3.2 and with proper temperature control during manufacturing, we see less than 0.3% conversion in our stability batches.

Q: How long does a 1.5% SA serum take to show results — what should we tell customers?

Based on the clinical data and our brand partners’ consumer studies, visible pore-refinement typically shows at 4 weeks with consistent use. Meaningful reduction in breakout frequency takes 8–12 weeks. We’d recommend setting consumer expectations at 8 weeks minimum for acne-specific claims — anything shorter and you’re setting up for returns.

Q: Our brand is clean/natural — can we still use salicylic acid?

Salicylic acid is naturally derived (from willow bark) and is accepted by most clean beauty standards including EWG and COSMOS-approved formulations at appropriate concentrations. The challenge is the preservative system and pH adjusters — some clean-label constraints make it harder to build a robust preservative system at low pH. We’ve solved this for several clean beauty clients using sodium phytate as chelator and a fermentation-derived preservative blend, but it adds cost and requires more rigorous challenge testing.

Q: What’s the minimum order quantity for a custom BHA toner versus a BHA serum?

For a standard BHA toner (water-thin, simple vehicle), MOQ is 1,000 units. For a BHA serum with a more complex vehicle or encapsulated SA, MOQ starts at 3,000 units. Both include one round of stability testing and ISO 11930 preservative challenge testing in the base price. Additional regulatory documentation (CPSR, OTC compliance package) is quoted separately.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.